Transgene Biotek has informed that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021, to consider and approve the unaudited standalone & consolidated financial results for the quarter and half year ended on 30th September 2021; and to examine and take note of the Limited Review Report as provided by the Statutory Auditor of the Company.
The above information is a part of company’s filings submitted to BSE.